Decipher Labs Peer Comparison

BSE: 524752

₹6.01

₹-0.01 (-0.17%)

As on 23-Sep-2026IST

Market cap

₹6 Cr

Revenue (TTM)

₹14 Cr

P/E Ratio

--

P/B Ratio

0.3

Div. Yield

0 %

Edit

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Market cap (₹ Cr)	6	37,857	27,713	26,763	28,045
Revenue (₹ Cr)	14	3,564	1,936	1,462	9,205
Net Profit (₹ Cr)	-3.06	414.00	288.22	387.35	-371.81
Net Margin (%)	-22.11	11.23	14.79	26.01	-3.93
RoE (%)	-15.39	8.38	29.77	25.18	-3.85
Price to Earnings	--	92.56	96.15	69.30	--
Price-To-Book	0.33	7.52	20.65	15.51	3.50

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Operating Revenue	13.55	3,564.00	1,935.80	1,461.80	9,205.28
Total Income	13.85	3,686.00	1,948.58	1,489.25	9,449.59
Total Expenditure	15.77	2,792.00	1,485.56	919.25	8,195.15
EBITDA	-2.23	772.00	450.24	542.56	1,010.13
Depreciation	0.53	226.00	50.83	37.68	857.51
EBIT	-2.76	546.00	399.41	504.88	152.62
Interest	0.00	217.00	40.84	3.77	342.73
Other Income	0.31	122.00	12.78	27.45	244.31
Exceptional Items	0.00	12.00	0.00	0.00	-216.88
Profit before Tax	-2.45	463.00	371.35	528.56	-162.68
Provision for Tax	0.62	49.00	83.14	141.21	209.13
Profit after Tax	-3.06	414.00	288.22	387.35	-371.81

Liabilities (₹ Cr)

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Shareholder's Funds	20.67	4,940.00	1,288.82	1,653.56	8,162.62
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	0.00	1,712.00	202.03	42.40	5,044.14
Current Liabilities	3.67	1,622.00	835.87	230.82	4,758.28
Total Liabilities	25.76	8,100.00	1,451.43	1,549.26	15,513.53

Assets (₹ Cr)

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Non-Current Assets	5.18	5,343.00	519.60	1,026.85	10,211.52
Current Assets	19.12	2,606.00	1,681.81	881.27	7,191.66
Total Assets	25.76	8,100.00	1,451.43	1,549.26	15,513.53
Total Debt*	0.24	1,859.00	393.17	8.18	4,720.27
Net Current Assets	15.45	984.00	845.94	650.46	2,433.38
Contingent Liabilities	--	770.26	12.25	15.38	99.76

Cashflow (₹ Cr)

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Cash From Operating Activities	-9.82	-22.00	159.18	118.34	892.30
Cash Flow from Investing Activities	3.07	-783.00	-64.81	-223.94	-477.46
Cash from Financing Activities	0.24	409.00	-39.81	261.12	-440.83
Net Cash Inflow / Outflow	-6.51	-396.00	54.56	155.52	-25.99

Ratios

Profitability Ratios

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
ROCE (%)	-28.39	4.07	26.97	20.14	6.61
ROE (%)	-15.39	8.38	29.77	25.18	-3.85
ROA (%)	-12.23	4.94	24.77	21.93	-2.21
EBIT Margin (%)	-20.35	15.32	20.63	34.54	1.66
Net Margin (%)	-22.11	11.23	14.79	26.01	-3.93
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Revenue Growth (%)	-25.15	18.37	46.65	40.90	0.78
EBIT Growth (%)	77.66	252.26	62.13	124.50	-70.53
Net Profit Growth (%)	67.60	377.85	89.49	104.15	-1,383.43
EPS Growth (%)	67.60	1,001.33	78.60	42.32	-484.84
Book Value Growth (%)	4.55	29.77	42.49	94.96	2.28

Valuation Ratios

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Price / Earnings	-1.98	95.00	94.68	69.29	-89.63
Price / Book Value	0.33	7.52	20.65	15.51	3.50
Dividend Yield (%)	0.00	0.00	0.09	0.08	0.00
EV/EBITDA	-1.57	50.93	61.36	48.96	31.86
Market Cap (₹ Cr)	10.61	23,064.69	0.00	19,988.69	29,731.27

Solvency Ratios

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debt to Equity	0.00	0.31	0.11	0.01	0.53
Short term debt to equity ratio	0.01	0.11	0.54	0.02	0.12
Current Ratio	5.22	1.61	2.01	3.82	1.51
Quick Ratio	5.21	1.06	1.14	2.82	0.87
Interest Coverage	-1,877.29	3.13	10.09	141.16	0.53

Operating Efficiency Ratios

	Decipher Labs	Wockhardt	Rubicon Research	Acutaas Chemicals	Piramal Pharma
Debtors to sales (%)	19.18	16.50	26.28	24.80	23.44
Asset Turnover	0.54	0.43	1.66	0.83	0.55
Receivable days	96.97	60.36	47.59	90.06	77.05
Inventory Days	0.00	64.42	62.58	61.02	77.13
Payable days	1,669.09	218.94	228.78	96.06	173.49
Cash Conversion Cycle	-1,572.13	-94.15	-118.62	55.02	-19.30

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.